Population screening for genetic disorders in the 21st century: evidence, economics, and ethics.
about
Review of Current International Decision-Making Processes for Newborn Screening: Lessons for AustraliaRecommendations for returning genomic incidental findings? We need to talk!Neurotalk: improving the communication of neuroscience researchThe Klinefelter syndrome: current management and research challenges.Dangerous and expensive screening and treatment for rare childhood diseases: the case of Krabbe disease.Funding decisions for newborn screening: a comparative review of 22 decision processes in EuropeA compendium of genome-wide associations for cancer: critical synopsis and reappraisal.The emergence of translational epidemiology: from scientific discovery to population health impact.EMQN best practice guidelines for the molecular genetic diagnosis of hereditary hemochromatosis (HH).Emerging issues in public health genomics.'Someday it will be the norm': physician perspectives on the utility of genome sequencing for patient care in the MedSeq ProjectA one-page summary report of genome sequencing for the healthy adultPoints to consider in assessing and appraising predictive genetic tests.Valuations of genetic test information for treatable conditions: the case of colorectal cancer screening.The promises of genomic screening: building a governance infrastructure. Special issue: genetics and democracy.Association of PNPLA3 rs738409 and TM6SF2 rs58542926 with health services utilization in a population-based study.Cell-free fetal DNA testing for fetal aneuploidy and beyond: clinical integration challenges in the US contextPrevalence, incidence, and age at diagnosis in Marfan Syndrome.Showing Value in Newborn Screening: Challenges in Quantifying the Effectiveness and Cost-Effectiveness of Early Detection of Phenylketonuria and Cystic Fibrosis.Genetics specialists' perspectives on disclosure of genomic incidental findings in the clinical setting.Quality of life utility values for hereditary haemochromatosis in Australia.Evaluating Harms in the Assessment of Net Benefit: A Framework for Newborn Screening Condition Review.The Use of Economic Evaluation to Inform Newborn Screening Policy Decisions: The Washington State Experience.Criteria for fairly allocating scarce health-care resources to genetic tests: which matter most?A framework to start the debate on neonatal screening policies in the EU: an Expert Opinion Document.Issues surrounding the health economic evaluation of genomic technologies.Postnatal screening for Klinefelter syndrome: is there a rationale?Risk counselling for family members in bipolar disorder and schizophrenia.Prenatal and preconception population carrier screening for cystic fibrosis in Australia: where are we up to?A Systematic Review and Narrative Synthesis of Health Economic Studies Conducted for Hereditary Haemochromatosis.Clinical penetrance in hereditary hemochromatosis: estimates of the cumulative incidence of severe liver disease among HFE C282Y homozygotes.Only a minority of sex chromosome abnormalities are detected by a national prenatal screening program for Down syndrome.Cancer Predisposition Cascade Screening for Hereditary Breast/Ovarian Cancer and Lynch Syndromes in Switzerland: Study Protocol.How Primary Care Providers Talk to Patients about Genome Sequencing Results: Risk, Rationale, and Recommendation.The Impact of Whole-Genome Sequencing on the Primary Care and Outcomes of Healthy Adult Patients: A Pilot Randomized Trial.Insufficient referral for genetic counseling in the management of hereditary haemochromatosis in portugal: a study of perceptions of health professionals requesting HFE genotyping.Ethical implications and practical considerations of ethnically targeted screening for genetic disorders: the case of hemoglobinopathy screening.Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it?Practice guideline: joint CCMG-SOGC recommendations for the use of chromosomal microarray analysis for prenatal diagnosis and assessment of fetal loss in Canada.Economic impact of screening for X-linked Adrenoleukodystrophy within a newborn blood spot screening programme
P2860
Q26781078-6C071693-F814-4994-8743-AFFDE39153CAQ26995124-F5B271A8-645C-4852-BB62-8DE39AF7E579Q28748970-93CC18D3-A233-4B65-8E2D-94CCA4C29FB5Q30276861-8FDE0F42-A114-4C20-93EC-97C93D53761BQ33583245-3698C694-B006-4900-BE56-C9E433B729DFQ33742237-4E545EE0-ED18-4124-AF16-B616CB0480D4Q33915049-99C3F227-1097-40EA-B6F3-2B708F764255Q34082166-8ABF40F6-1560-437D-A66B-198F825B70C7Q34483947-C3E35AF3-71E3-4910-8081-300B9DC2286FQ34496940-BA27C33A-D3B8-4010-A52B-F3C8A2044DA9Q35012563-6A7957BD-BF57-444A-B5A2-1481F22B6FE9Q35143268-109C3CC2-08A5-4CA9-BC20-C1E384E2F321Q35263641-7AD55D4D-3F59-4A5E-BD41-771B4E12B436Q35822142-A0E2457A-BB1B-419E-86F9-AFEB95E04314Q35854560-3529243E-02EB-4B00-BB3F-6F105A2A50A0Q35914994-8AB4F163-7B23-45BD-BC0D-9793F1C25953Q36321452-D9BC37BB-79F8-40D3-9633-1B2C56512F4FQ36344156-3F3F03C9-F1B0-4970-9BBD-FFEBE70DED4DQ36390515-293769E0-9CAA-4A1D-B76E-D94F3132B91BQ36468074-34E6992F-3295-46B4-9856-9254DED620B3Q36629254-57068A3A-7DED-44CB-A061-15EAFCECC861Q36762922-0ACF7C96-29EA-4899-8300-0F913F27D675Q37015264-1702F42C-8EC7-4683-9259-3914EBB7589AQ37397621-8A06863E-1412-4640-8CFB-EB96B1C757F5Q37397665-61526E52-FABC-4C43-8CCE-E16762F7A58EQ37541151-E476AEB3-9BCA-4C6B-988B-5BCCC840BF59Q37827896-A69D1B8D-D6FE-4F13-B9DC-C6544C216EDFQ38058638-9DEA5E5D-838B-45DE-A781-DD249EE1458FQ38263296-EADAE40A-38A8-4494-A6B5-D7432FF74951Q38563037-9183C615-B771-4CCF-A27F-005FC654F833Q38644627-C09D8B4D-A8BD-4410-BF83-B6D4BCE7501FQ38976722-E65710DB-D543-4377-A9B8-BD1AACFF5B84Q42370445-5F242C62-368D-4C81-9368-91F264C37D2DQ47709349-87F2C6CF-0A68-4817-995E-9B0A99E8B8C3Q47717402-330899DA-A1BF-4E0A-ACF7-2E63CA367EB7Q47812536-6D81E639-2510-4F59-A152-017B5B27E539Q47986810-B139BCD4-01C5-4BAB-8428-D5F0BDF9ADFEQ50747047-B5A4B3F9-90A9-4E5C-98BC-60D37DEB57EAQ53825282-EB1E4FB4-9201-4C28-82A8-A5B486D17E00Q57476641-E06D6F01-F8B4-439D-920D-1A0784EDDF75
P2860
Population screening for genetic disorders in the 21st century: evidence, economics, and ethics.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Population screening for genet ...... idence, economics, and ethics.
@en
Population screening for genet ...... idence, economics, and ethics.
@nl
type
label
Population screening for genet ...... idence, economics, and ethics.
@en
Population screening for genet ...... idence, economics, and ethics.
@nl
prefLabel
Population screening for genet ...... idence, economics, and ethics.
@en
Population screening for genet ...... idence, economics, and ethics.
@nl
P2093
P356
P1476
Population screening for genet ...... idence, economics, and ethics.
@en
P2093
M C Cornel
S D Grosse
W H Rogowski
W J Dondorp
P304
P356
10.1159/000226594
P577
2009-06-29T00:00:00Z